Skip to main content

News

Inflammatory Arthritis and Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or recurrent

Biosimilar Bonanza in 2023 (12.9.2022)

Dr. Jack Cush reviews more than a dozen news and journal articles from this past week on RheumNow.com. 

Telemedicine Updates

Several recent articles inform us of recent trends in Telemedicine.

ACR Urges Congress to Prioritize Medicare Pay Cuts, Prior Authorization, and Telehealth

As the legislative session comes to a close, the American College of Rheumatology (ACR) is calling on members of Congress to include the Improving Seniors’ Timely Access to Care Act (H.R. 3173/S. 3018), the Supporting Medicare Providers Act of 2022 (H.R.

Xeljanz Cancer Risks Detailed

MedPage Today

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

The Top 10 Research Priorities in Psoriatic Arthritis

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

Multi-ancestry analysis reveals novel genetic loci associated with Osteoarthritis

The first large multi-ancestry genetics study of osteoarthritis (OA) has found 10 novel OA-associated genetic loci, and results showed some of the OA-associated regions are robustly found in every population ancestry studied. 

TARGET Trial - Cardiovascular Risk Reduction in Rheumatoid Arthritis

A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).

Comparing Biosimilar Growth in the US, Germany, and Switzerland

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.

Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth

Pregnant women with systemic lupus erythematosus (SLE) were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to national administrative data.

Rheum Manpower Needs - More Programs! (12.2.2022)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

×